🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats to the Multicancer Early Detection (MCED) Consortium on the release of their position paper. We are honored that Adela's Chief Medical Officer Anne-Renee Hartman serves on the Executive Committee of this important initiative.

Check out the hottest private biotech companies in Canada: Adela • Deep Genomics • Inversago Pharma •Notch Therapeutics • Virogin Biotech 👇🏻 #biotech #lifesciences #news zpr.io/U5zxy9np7ZWh

Adela will be presenting data at #AACR23 demonstrating the ability of our genome-wide methylome enrichment platform to detect multiple cancer types. The embargo on this abstract will lift on April 16 at 1:30 PM ET. adelabio.com/press/adela-to…

Adela presented data today at #AACR23 demonstrating the ability of our genome-wide methylome enrichment platform to detect a broad set of diverse cancers in early stages (stage I and II), when treatment can be most effective. adelabio.com/press/adela-pr…

We’re thrilled to welcome Alan Williams to Adela as Chief Operating Officer! Alan brings proven and deep expertise from his senior executive roles at Somalogic, Thermo Fisher Scientific (Ion Torrent), and Affymetrix. prnewswire.com/news-releases/…

We are excited to announce $48M in financing from investors F-Prime, OrbiMed, Deerfield Management, Decheng Capital, RA Capital Management, and Labcorp! prnewswire.com/news-releases/…

Adela will be presenting data at #ESMO23 demonstrating strong prognostic prediction capabilities of our genome-wide methylome enrichment platform in Head and Neck Cancer and Renal Cell Carcinoma adelabio.com/press/adela-pr…

Adela is presenting data today during the Plenary Abstract Session at the 2023 Multidisciplinary Thoracic Cancers Symposium demonstrating strong prognostic prediction capabilities in lung cancer #thoracic23 adelabio.com/press/adela-pr…

We're thrilled to announce that Lisa Alderson has been appointed as Adela's permanent CEO. Lisa is a seasoned healthcare CEO who brings over 20 years of experience building early-stage companies at the intersection of technology and healthcare. prnewswire.com/news-releases/…

Exciting panel on New Approaches of Liquid Biopsy awaits at #PMWC24. Feat. experts Victor Velculescu, David Sidransky Johns Hopkins Medicine, Daniel De Carvalho University of Toronto, Dan Landau NY Genome Center. Catch them on 2024-01-25, Track 4, 2.00 P.M. More at: pmwcintl.com/program

Attending Precision Medicine World Conference 2024? Don't miss these sessions on liquid biopsy featuring Adela's Chief Medical Officer, Anne-Renee Hartman, MD and Chief Scientific Officer Daniel De Carvalho.

Adela is presenting at #AACR2024! Highlights include data in head & neck cancer from our tissue-agnostic MRD assay, and Chief Scientific Officer Daniel De Carvalho chairing the Plenary Session “Discovery Science in Early Cancer Biology and Interception”. adelabio.com/press/adela-to…

Adela presented data at #AACR24 from our MRD Assay demonstrating the ability to predict recurrence in head & neck cancer prnewswire.com/news-releases/…

We're excited to share that training data demonstrating the ability of our MRD product to predict recurrence in Head & Neck Cancer will be presented at #ASCO24 in an Oral Abstract Presentation. prnewswire.com/news-releases/…

If you are attending #ESMO24 don't miss the oral presentation of our clinical validation results demonstrating the ability of our MRD test to predict and monitor for recurrence in patients with head & neck cancer.

Today we are celebrating a significant milestone for Adela: the simultaneous publication of our clinical validation study for our tissue-agnostic MRD test in Head & Neck cancer in Annals of Oncology and its presentation at #ESMO24.  prnewswire.com/news-releases/…

📢@ESMO24 concomitant paper: Clinical validation of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies. #ESMO24 #HeadandNeckCancer Adela UHN Research Daniel De Carvalho Scott Bratman tinyurl.com/2bkueo7a

Watch the highlights of the clinical validation study of Adela's MRD test in head & neck cancer delivered by Medical Oncologist Dr. Geoff Liu of Princess Margaret Cancer Centre, University Health Network (UHN). annalsofoncology.org/video-do/clini… UHN Research

Congratulations to Adela’s Co-Founder and Chief Scientific Officer Daniel De Carvalho on his receipt of the 2025 Canada Gairdner Momentum Award!

We're excited to announce two presentations at #ASCO25 demonstrating the ability of Adela's tissue-agnostic test for MRD Detection and Response Monitoring to predict progression and identify non-responders to immunotherapy in solid tumors. prnewswire.com/news-releases/…